Women with endometriosis may soon be able to have a simple blood test to diagnose their disease thanks to a breakthrough by Proteomics International Ltd. that has developed a plasma protein biomarker panel that identifies all stages of endometriosis.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Carestream, Fesariustherapeutics, Oxos, Roche, Ventris.
Johnson & Johnson halted the limited rollout of its Varipulse pulsed field ablation system on Jan. 5 to “investigate the root causes of four reported neurovascular events in the U.S. external evaluation.” So far, just 130 cases have been completed in the U.S. since the company received U.S. FDA approval in November for use in paroxysmal atrial fibrillation.
Fire1 Ltd. secured $120 million in financing to conduct a pivotal trial for its heart failure management system, Norm. The technology measures fluid in the inferior vena cava (IVC) and is expected to help the millions of people living with heart failure manage their condition and get their normal life back.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aerwave, Argon Medical, Biofidelity, Biostem, Caresyntax, Cellcarta, Endostream, Genialis, Inify, Kaneka, Peerbridge, Qaelon, Roivios, Tempus AI, Tricares.
RSS
